Jefferies Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $275

Futu NewsJan 10 21:33 · Ratings

ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders

BenzingaJan 8 20:21

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer's and Related Disorders ICON Survey

Business WireJan 8 20:00

ICON Plc Draws Bullish Views at RBC on Attractive Valuation

Seeking AlphaJan 8 03:28

Icon Shares Are Trading Higher After RBC Capital Initiated Coverage on the Stock With an Outperform Rating and Announced a Price Target of $263.

BenzingaJan 8 02:54

ICON Up Over 5%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk

Dow JonesJan 7 23:35